Synonyms: Aklief® | CD5789 | compound 15b [PMID: 29706423]
trifarotene is an approved drug (FDA (2019))
Compound class:
Synthetic organic
Comment: Trifarotene (CD5789) is a RARγ-selective agonist that was developed as a topical anti-acne therapeutic [1-2,4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
RARγ isotype-selectivity is predicted to endow trifarotene with an improved safety margin (but equivalent efficacy) compared to the existing clinically used dual RARβ/γ agonists tazarotene and adapalene. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Acne vulgaris |
Disease Ontology:
DOID:6543 OMIM: 604324 |
Phase 3 clinical candidate for acne vulgaris- see NCT02189629. Retinoid drugs reduce the proinflammatory factors and disrupt the immunoinflammatory cascade associated with acne vulgaris. |